Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Promestriene→

Promestriene Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
39219-28-8
Molecular formula
C22H32O2
Molecular weight
328.5 g/mol
Drug class
Synthetic topical oestrogenlocally acting estradiol derivative
Mechanism of action
A lipophilic estradiol derivative that activates local oestrogen receptors in vaginal and vulvar tissues, promoting epithelial maturation, glycogen accumulation, restoration of the acidic vaginal environment and improvement in mucosal trophism. Systemic absorption is low with recommended local use.
Indications / reported uses
  • Local treatment of vulvovaginal atrophy and related symptoms of oestrogen deficiency, including vaginal dryness and irritation, according to the specific product authorisation.

Sources: https://pubchem.ncbi.nlm.nih.gov/#query=promestriene · https://www.ncbi.nlm.nih.gov/mesh/?term=promestriene · https://www.ema.europa.eu/en/medicines/human/EPAR/colpotrophine · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Promestriene Environmental Risk Assessment (ERA) (the Promestriene ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.